Table 2.
Change in Studied Variables After Intervention According to Study Group
| Spironolactone (n=100) | Placebo (n=98) | |
|---|---|---|
| Studied efficacy endpoints | ||
| Mean LVMI, g/m2.7 (men) | ||
| Baseline | 52.31±17.59 | 52.87±21.43 |
| 2 years | 45.52±14.26 | 56.18±18.02 |
| Mean change from baseline vs placebo (95% CI) | −10.1 (−11.0 to −9.2) | – |
| P value | .006 | – |
| Mean LVMI, g/m2.7 (women) | ||
| Baseline | 46.37±14.66 | 48.29±14.25 |
| 2 years | 42.05±13.19 | 52.68±17.42 |
| Mean change from baseline vs placebo (95% CI) | −8.7 (−9.4 to −8.0) | – |
| P value | .008 | – |
| Mean LVEF, % | ||
| Baseline | 61.78±10.33 | 61.29±11.51 |
| 2 years | 64.29±11.02 | 58.73±9.67 |
| Mean change from baseline vs placebo (95% CI) | 5.1 (4.7 to 5.5) | – |
| P value | .027 | – |
| Mean FMD, % | ||
| Baseline | 7.05±1.49 | 6.88±1.72 |
| 2 years | 9.88±3.02 | 6.31±1.89 |
| Mean change from baseline vs placebo (95% CI) | 3.4 (3.1 to 3.7) | – |
| P value | .033 | – |
| Mean number of antihypertensive drugs | ||
| Baseline | 4.52±1.88 | 4.97±2.85 |
| 2 years | 3.29±1.51 | 5.36±2.44 |
| Mean change from baseline vs placebo (95% CI) | −1.6 (−1.7 to −1.5) | – |
| P value | .041 | – |
| Laboratory variables | ||
| Mean plasma potassium | ||
| Baseline | 4.12±0.42 | 3.96±0.51 |
| 2 years | 5.32±0.68 | 4.68±0.32 |
| Mean change from baseline vs placebo (95% CI) | 0.48 (0.42 to 0.54) | – |
| P value | .13 | – |
| Mean BNP, pg/mL | ||
| Baseline | 77.32±21.72 | 74.85±19.27 |
| 2 years | 75.38±19.47 | 81.69±17.41 |
| Mean change from baseline vs placebo (95% CI) | −8.8 (−9.4 to −8.2) | – |
| P value | .07 | – |
| Mean plasma NT‐proBNP, pg/mL | ||
| Baseline | 338.49±121.31 | 357.65±89.52 |
| 2 years | 337.42±117.58 | 360.31±107.25 |
| Mean change from baseline vs placebo (95% CI) | −3.73 (−7.4 to −0.1) | – |
| P value | .69 | – |
| Mean plasma aldosterone, pg/mL | ||
| Baseline | 56.42±21.33 | 60.35±19.05 |
| 2 years | 58.25±20.47 | 67.21±23.59 |
| Mean change from baseline vs placebo (95% CI) | −5.0 (−6.0 to −4.1) | – |
| P value | .71 | – |
Abbreviations: BNP, brain natriuretic peptide; CI, confidence interval; FMD, flow‐mediated dilation; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; NT‐proBNP, N‐terminal pro–B‐type natriuretic peptide.